9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care

9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care

The hemodynamic stability of surgical and critically ill patients hinges on the precise pharmacological modulation of cardiac inotropy, chronotropy, systemic vascular resistance (SVR), and venous capacitance. Achieving optimal tissue perfusion while avoiding excessive myocardial oxygen consumption ($MVO_2$) requires comprehensive mastery of autonomic receptor signaling, intracellular second messenger cascades, and the pharmacodynamic profiles of sympathomimetic amines, inodilators, and non-adrenergic vasopressors.

---

1. Adrenergic and Dopaminergic Receptor Signal Transduction

Adrenergic and dopaminergic receptors belong to the superfamily of seven-transmembrane domain G-protein-coupled receptors (GPCRs). Their downstream physiological responses depend on the specific heterotrimeric G-protein (alpha, beta, gamma subunits) coupled to their intracellular loops.

                         [ ADRENERGIC RECEPTOR SIGNALING ]
                                         |
        +--------------------------------+--------------------------------+
        |                                |                                |
  [ G_q-COUPLED ]                  [ G_i-COUPLED ]                  [ G_s-COUPLED ]
   alpha_1 Receptors                alpha_2 & D_2 Receptors          beta_1, beta_2, & D_1 Receptors
        |                                |                                |
        v                                v                                v
Phospholipase C (PLC)             Inhibits Adenylyl Cyclase        Stimulates Adenylyl Cyclase
        |                                |                                |
  +-----+-----+                          v                                v
  |           |                   Decreased cAMP                    Elevated cAMP
  v           v                          |                                |
 IP_3        DAG                  Decreased PKA                     Activates PKA
  |           |                          |                                |
  v           v                          v                                v
Ca2+ Efflux  Activates PKC       Reduced Ca2+ Influx               Phosphorylates Target
from SR      Phosphorylates      Enhanced K+ Efflux                Proteins (CaV1.2, PLN,
Vascular     Regulatory          Presynaptic Autoinhibition        RyR2, Troponin I,
Smooth       Proteins            Sedation, Analgesia,              MLCK in smooth muscle)
Muscle                           Sympatholysis                     Inotropy / Vasodilation
Contraction

Alpha-1 ($\alpha_1$) Adrenoceptors

• Signaling Cascade: $\alpha_1$ receptors couple to the $G_q$ protein. Agonist binding activates phospholipase C-$\beta$ (PLC), which cleaves membrane phosphatidylinositol 4,5-bisphosphate ($\text{PIP}_2$) into two active second messengers:
  1. Inositol 1,4,5-trisphosphate ($\text{IP}_3$): Diffuses through the cytoplasm to bind ligand-gated $\text{IP}_3$ receptor channels on the sarcoplasmic reticulum (SR), triggering rapid efflux of stored calcium ($Ca^{2+}$) into the cytosol.
  2. Diacylglycerol (DAG): Remains in the plasma membrane and, together with elevated cytosolic $Ca^{2+}$, activates protein kinase C (PKC). PKC phosphorylates calponin, caldesmon, and other regulatory proteins, augmenting the sensitivity of contractile myofilaments to calcium.
• Vascular Smooth Muscle Effect: Cytosolic $Ca^{2+}$ binds calmodulin to form the $Ca^{2+}\text{-calmodulin}$ complex, which activates myosin light chain kinase (MLCK). MLCK phosphorylates the 20-kDa regulatory light chain of myosin, initiating actin-myosin cross-bridge cycling and intense arteriolar and venular vasoconstriction.

Alpha-2 ($\alpha_2$) Adrenoceptors

• Signaling Cascade: $\alpha_2$ receptors couple to the $G_i$ (inhibitory) protein. Activation inhibits adenylyl cyclase, depleting intracellular cyclic adenosine monophosphate ($\text{cAMP}$) and reducing protein kinase A (PKA) activity. In addition, the liberated $G_{\beta\gamma}$ dimer directly inhibits voltage-gated N-type calcium channels and activates inwardly rectifying potassium channels ($GIRK$), producing cellular hyperpolarization.
• Physiological Actions:
  • Presynaptic Autoreceptors: Located on postganglionic sympathetic nerve terminals; activation exerts negative feedback inhibition, shutting down exocytotic release of endogenous norepinephrine.
  • Central Nervous System: Located in the locus coeruleus of the brainstem; activation suppresses central sympathetic outflow, inducing sedation, hypnosis, anxiolysis, and analgesia (the target of clonidine and dexmedetomidine).
  • Postsynaptic Vascular Receptors: Located on vascular smooth muscle; direct stimulation causes modest peripheral vasoconstriction (often observed as transient hypertension during rapid intravenous boluses of dexmedetomidine).

Beta-1 ($\beta_1$) Adrenoceptors

• Signaling Cascade: $\beta_1$ receptors couple to the $G_s$ (stimulatory) protein. Agonist binding triggers the $G_{\alpha s}$ subunit to activate membrane-bound adenylyl cyclase, converting adenosine triphosphate (ATP) to $\text{cAMP}$. Elevated $\text{cAMP}$ binds the regulatory subunits of protein kinase A (PKA), releasing active catalytic subunits that phosphorylate multiple critical cardiac targets:
  1. L-type Calcium Channels ($Ca_V1.2$): Increases open-state probability, augmenting inward trigger $Ca^{2+}$ current ($I_{\text{Ca,L}}$) during Phase 2 of the cardiac action potential.
  2. Ryanodine Receptors (RyR2): Augments calcium-induced calcium release (CICR) from the sarcoplasmic reticulum.
  3. Phospholamban (PLN): Phosphorylation of phospholamban relieves its tonic inhibitory brake on the sarco/endoplasmic reticulum $Ca^{2+}$-ATPase (SERCA2a) pump. SERCA2a accelerates the reuptake of cytosolic calcium back into the SR during diastole.
  4. Troponin I: Phosphorylation lowers myofilament calcium affinity, facilitating prompt cross-bridge detachment during relaxation.
• Cardiovascular Effects:
  • Positive Inotropy: Increased contractile force due to augmented peak systolic intracellular $Ca^{2+}$.
  • Positive Chronotropy: Increased heart rate because cAMP binds directly to hyperpolarization-activated cyclic nucleotide-gated (HCN4) channels, increasing the pacemaker funny current ($I_f$) in the sinoatrial (SA) node, while PKA augments $I_{\text{Ca,L}}$.
  • Positive Dromotropy: Accelerated conduction velocity through the atrioventricular (AV) node via enhanced $I_{\text{Ca,L}}$.
  • Positive Lusitropy: Accelerated myocardial relaxation during diastole (mediated primarily by phospholamban phosphorylation), preserving diastolic ventricular filling time during catecholamine-induced tachycardia.

Beta-2 ($\beta_2$) Adrenoceptors

• Signaling Cascade: $\beta_2$ receptors also couple to $G_s$, stimulating adenylyl cyclase and generating $\text{cAMP}$ to activate PKA.
• Vascular and Bronchial Smooth Muscle Effect: Unlike cardiac myocytes, elevated $\text{cAMP}$ and active PKA in smooth muscle promote relaxation (vasodilation and bronchodilation). PKA phosphorylates myosin light chain kinase (MLCK), drastically reducing MLCK's affinity for the $Ca^{2+}\text{-calmodulin}$ complex. Concurrently, PKA stimulates large-conductance calcium-activated potassium ($BK_{\text{Ca}}$) channels, hyperpolarizing the cell membrane and reducing voltage-gated calcium entry, and enhances calcium extrusion via the plasma membrane $Ca^{2+}$-ATPase.

Dopaminergic ($D_1$ and $D_2$) Receptors

• $D_1$ Receptors: Postsynaptic GPCRs coupled to $G_s$. Located predominantly in renal, mesenteric, coronary, and cerebral vascular beds. Activation stimulates adenylyl cyclase, elevating $\text{cAMP}$ and driving smooth muscle relaxation and vasodilation, which enhances renal cortical blood flow and promotes natriuresis.
• $D_2$ Receptors: Presynaptic GPCRs coupled to $G_i$ on sympathetic nerve terminals and autonomic ganglia. Activation inhibits adenylyl cyclase, attenuating exocytotic norepinephrine release and blunting sympathetic transmission.

---

2. Endogenous and Synthetic Catecholamines

Catecholamines are organic compounds consisting of an aromatic benzene ring with two adjacent hydroxyl groups (catechol) and an ethylamine side chain. Endogenous catecholamines are synthesized sequentially from the amino acid L-tyrosine: $\text{L-Tyrosine} \xrightarrow{\text{Tyrosine hydroxylase}} \text{L-DOPA} \xrightarrow{\text{AADC}} \text{Dopamine} \xrightarrow{\text{Dopamine }\beta\text{-hydroxylase}} \text{Norepinephrine} \xrightarrow{\text{PNMT}} \text{Epinephrine}$

                                  HO
                                    \   CH - CH_2 - NH - R
                                     |  |
                                    /   OH
                                  HO
                            [ Catecholamine Backbone ]
                 Epinephrine: R = -CH_3
                 Norepinephrine: R = -H
                 Isoproterenol: R = -CH(CH_3)_2  (bulky alkyl group -> pure beta)

Epinephrine (Adrenaline)

• Receptor Profile: Non-selective agonist across $\alpha_1, \alpha_2, \beta_1,$ and $\beta_2$ adrenoceptors.
• Dose-Dependent Hemodynamics:
  • Low Dose ($0.01 - 0.05\text{ mcg/kg/min}$): Predominant $\beta_1$ and $\beta_2$ stimulation. Produces marked positive inotropy, chronotropy, and lusitropy. Peripheral $\beta_2$ stimulation outbalances $\alpha_1$ tone, leading to a decrease in systemic vascular resistance (SVR) and diastolic blood pressure, while systolic blood pressure rises due to increased stroke volume. Pulse pressure widens and cardiac output increases.
  • High Dose ($>0.1 - 0.2\text{ mcg/kg/min}$): Overcoming $\alpha_1$ agonism dominates over $\beta_2$-mediated vasodilation. Produces profound generalized vasoconstriction, elevated SVR, increased mean arterial pressure (MAP), and renal/splanchnic vascular constriction, while maintaining strong $\beta_1$ cardiac contractility.
• Metabolic Effects (The $\beta_2$ Cascade):
  • Hyperlactatemia: Epinephrine stimulates skeletal muscle cell-surface $\beta_2$ adrenoceptors coupled to adenylyl cyclase. The surge in $\text{cAMP}$ activates glycogen phosphorylase, driving intense glycogenolysis and accelerated aerobic glycolysis. Pyruvate production rapidly outpaces the catalytic capacity of mitochondrial pyruvate dehydrogenase (PDH). Excess cytosolic pyruvate is converted directly to lactate by lactate dehydrogenase ($LDH$): $\text{Pyruvate} + \text{NADH} + \text{H}^+ \xrightleftharpoons{\text{LDH}} \text{Lactate} + \text{NAD}^+$ This mechanism represents Type B hyperlactatemia (aerobic, non-hypoxic lactate production), which must not be misconstrued as tissue hypoperfusion or cellular hypoxia.
  • Hyperglycemia: $\beta_2$ receptor stimulation activates hepatic glycogenolysis and gluconeogenesis, while concurrent $\alpha_2$ stimulation on pancreatic $\beta$-islet cells inhibits insulin secretion.
  • Hypokalemia: $\beta_2$ receptor activation stimulates the electrogenic sarcolemmal $\text{Na}^+/\text{K}^+$-ATPase pump in skeletal muscle, driving an inward shift of potassium ions from the extracellular to the intracellular space.

Norepinephrine (Noradrenaline)

• Receptor Profile: Potent, direct $\alpha_1$ and $\alpha_2$ agonist, with moderate $\beta_1$ inotropic activity and negligible $\beta_2$ affinity.
• Hemodynamic Profile: Norepinephrine is the first-line vasopressor in septic shock and vasodilatory hypotension (e.g., post-cardiopulmonary bypass vasoplegia, neuroaxial-induced sympathectomy). By stimulating $\alpha_1$ receptors on resistance arterioles, it markedly elevates SVR and MAP.
• Venous Capacitance and Preload Recruitment: Norepinephrine stimulates $\alpha_1$ receptors on muscular venules and large veins (the splanchnic venous capacitance reservoir). Venoconstriction converts unstressed blood volume into stressed blood volume, increasing mean systemic filling pressure ($P_{\text{msf}}$) and driving venous return to the right atrium. Through this mechanism, stroke volume and cardiac output are preserved or augmented despite increased afterload.
• Reflex Chronotropy: Although direct $\beta_1$ stimulation increases sinus node automaticity, the sudden surge in MAP activates arterial baroreceptors in the carotid sinus and aortic arch. Increased glossopharyngeal (CN IX) and vagal (CN X) afferent traffic to the nucleus tractus solitarius triggers compensatory vagal efferent discharge, which often counterbalances direct $\beta_1$ tachycardia, producing a neutral or slightly reduced heart rate.

Phenylephrine

• Receptor Profile: Pure, synthetic, direct-acting $\alpha_1$ adrenoceptor agonist devoid of $\beta$-adrenergic activity.
• Hemodynamic Profile: Produces rapid, dose-dependent arterial vasoconstriction and venoconstriction, increasing SVR, MAP, and central venous pressure ($CVP$).
• Reflex Bradycardia and Cardiac Output Depression: In the absence of $\beta_1$ inotropic stimulation, the robust baroreceptor reflex triggered by phenylephrine induces vagal bradycardia. Concurrently, the abrupt increase in left ventricular afterload without augmented inotropy frequently causes a 15% to 25% drop in cardiac output and stroke volume in patients with normal or depressed baseline ventricular function. It is primarily indicated for drug-induced vasodilatory hypotension with concurrent tachycardia.

Ephedrine

• Receptor Profile: Mixed-acting sympathomimetic amine. It acts predominantly via an indirect mechanism, taken up by presynaptic neuronal uptake-1 transporters to displace and release endogenous stored norepinephrine from vesicles into the synaptic cleft. It also exerts weak, direct agonist actions at $\alpha_1, \beta_1,$ and $\beta_2$ receptors.
• Hemodynamic Actions: Increases heart rate, stroke volume, SVR, and arterial blood pressure.
• Tachyphylaxis: Repeated administration produces rapid pharmacological tolerance (tachyphylaxis). This phenomenon results from the progressive depletion of vesicular norepinephrine stores in peripheral sympathetic varicosities and down-regulation/desensitization of postsynaptic receptors.
• Obstetric Use: Historically favored in obstetric anaesthesia for post-spinal hypotension because it preserves uterine artery blood flow via endogenous $\beta_2$ stimulation and indirect vasopressor actions. However, modern evidence confirms that phenylephrine infusions maintain maternal arterial pressure with less fetal acidosis (ephedrine crosses the placenta and stimulates fetal metabolism, causing mild fetal hyperlactatemia).

Dopamine

• Receptor Profile: Endogenous catecholamine displaying classic dose-dependent receptor affinity:
  • Low Dose ($0.5 - 2.0\text{ mcg/kg/min}$): Selectively activates postsynaptic vascular $D_1$ receptors in the renal, mesenteric, and coronary circulations, promoting vasodilation and natriuresis.
  • Intermediate Dose ($2.0 - 10.0\text{ mcg/kg/min}$): Stimulates cardiac $\beta_1$ adrenoceptors directly and promotes presynaptic norepinephrine release, augmenting myocardial contractility, heart rate, and cardiac output.
  • High Dose ($>10.0\text{ mcg/kg/min}$): $\alpha_1$ adrenoceptor agonism predominates, overcoming dopaminergic vasodilation to cause intense generalized vasoconstriction and elevated SVR.
• Fallacy of "Renal-Dose" Dopamine: Extensive multicenter randomized controlled trials (such as the ANZICS trial) demonstrated that low-dose dopamine neither prevents nor mitigates acute kidney injury in critically ill patients. Dopamine is also associated with an increased incidence of tachyarrhythmias (atrial fibrillation, sinus tachycardia, ventricular ectopy) and endocrine suppression (inhibiting anterior pituitary prolactin and thyroid-stimulating hormone release).

Dobutamine

• Receptor Profile: Synthetic catecholamine administered as a 50:50 racemic mixture. The $(+)$-enantiomer is a potent $\beta_1$ agonist and an $\alpha_1$ antagonist; the $(-)$-enantiomer is a selective $\alpha_1$ agonist. When administered clinically, the net result is predominant $\beta_1$ agonism with mild $\beta_2$ and minimal $\alpha_1$ activity ($\beta_1 > \beta_2 > \alpha_1$).
• Hemodynamic Profile: Powerful inotrope with modest peripheral vasodilation (an "inodilator"). Dobutamine increases cardiac index, stroke volume, and heart rate while lowering left ventricular end-diastolic pressure (LVEDP) and systemic vascular resistance.
• Oxygen Demand Hazard: Increases myocardial contractility and heart rate simultaneously, producing an inescapable rise in myocardial oxygen consumption ($MVO_2$). In patients with fixed coronary artery disease, dobutamine can precipitate acute regional myocardial ischemia and ventricular arrhythmias.

---

3. Phosphodiesterase-3 (PDE3) Inhibitors: Milrinone and Enoximone

Phosphodiesterase enzymes catalyze the hydrolytic breakdown of cyclic purine nucleotides ($\text{cAMP}$ and $\text{cGMP}$) into inactive 5'-nucleotide monophosphates. Phosphodiesterase-3 (PDE3) is the primary intracellular isoform expressed in cardiac myocytes and vascular smooth muscle that degrades $\text{cAMP}$.

                         [ PDE3 INHIBITOR MECHANISM ]
                                       |
                   Inhibition of Phosphodiesterase-3 (PDE3)
                                       |
                   Prevents Hydrolysis: cAMP -> 5'-AMP
                                       |
        +------------------------------+------------------------------+
        |                                                             |
[ CARDIAC MYOCYTE ]                                           [ VASCULAR SMOOTH MUSCLE ]
Elevated Intracellular cAMP                                   Elevated Intracellular cAMP
        |                                                             |
Activates PKA                                                 Activates PKA
        |                                                             |
Phosphorylates CaV1.2 & Phospholamban                         Phosphorylates & Inhibits MLCK
        |                                                             |
Augments Peak Systolic Ca2+ Influx                            Reduced Phosphorylation of Myosin Light Chains
Accelerates Diastolic SR Ca2+ Reuptake (SERCA2a)              Hyperpolarization via BK_Ca Channels
        |                                                             |
Positive Inotropy + Enhanced Lusitropy                        Systemic & Pulmonary Vasodilation
        |                                                             |
        +------------------------------+------------------------------+
                                       |
                                       v
                          [ NET INODILATOR EFFECT ]
                    Increased Stroke Volume & Cardiac Index
                    Decreased Left & Right Ventricular Afterload
                    Decreased Pulmonary Vascular Resistance (PVR)

Cellular Mechanism

• Myocardium: Milrinone and enoximone competitively inhibit PDE3, elevating cytosolic $\text{cAMP}$ levels independently of cell-surface beta-receptors. Activation of PKA increases calcium entry through L-type calcium channels during systole and accelerates calcium sequestration via SERCA2a during diastole. This produces positive inotropy and enhanced lusitropy without the receptor down-regulation associated with chronic beta-agonist infusions.
• Vascular Smooth Muscle: In systemic resistance vessels and pulmonary arterial beds, elevated $\text{cAMP}$ promotes PKA phosphorylation of MLCK, blocking its catalytic activity. Concurrently, PKA activates large-conductance $Ca^{2+}$-activated $K^+$ channels, resulting in marked systemic arterial vasodilation, venodilation, and pulmonary vasodilation.

Clinical Pharmacology and Indications

• Inodilator Niche: Milrinone is uniquely suited for patients with acute biventricular failure, low cardiac output states post-cardiopulmonary bypass, and pulmonary hypertension with right ventricular dysfunction. It unloads the right ventricle by reducing pulmonary vascular resistance (PVR) while simultaneously augmenting right ventricular contractile performance.
• Myocardial Oxygen Economy: Unlike pure beta-agonists, the marked reduction in ventricular wall tension (afterload reduction) offsets the metabolic cost of enhanced contractility, minimizing net increases in $MVO_2$.
• Pharmacokinetics and Toxicity: Milrinone is cleared predominantly ($>85\%$) unchanged by renal tubular excretion and glomerular filtration. Its elimination half-life is 2 to 4 hours in healthy subjects but extends up to 10 to 12 hours in acute kidney injury. An intravenous loading bolus ($50\text{ mcg/kg}$) frequently triggers profound systemic hypotension and should be omitted or drastically reduced in hemodynamically unstable patients; maintenance infusion rates range from $0.375 - 0.75\text{ mcg/kg/min}$.

---

4. Calcium Sensitizers: Levosimendan

Levosimendan represents a novel class of inotropic agents operating downstream of intracellular calcium transients, avoiding the cellular calcium overload that characterizes classic sympathomimetics.

                         [ LEVOSIMENDAN MECHANISM ]
                                      |
        +-----------------------------+-----------------------------+
        |                                                           |
[ CARDIAC TROPONIN C ]                                      [ VASCULAR SMOOTH MUSCLE ]
Binds to Ca2+-saturated Amino-Terminal                      Opens ATP-Sensitive Potassium
Domain of Cardiac Troponin C (cTnC)                         Channels (K_ATP) on Plasma Membrane
        |                                                           |
Stabilizes Active Cross-Bridge Conformation                 Potassium Efflux -> Hyperpolarization
Without Increasing Peak Cytosolic Free Ca2+                 Closure of Voltage-Gated L-type Ca2+ Channels
        |                                                           |
Augments Systolic Force (Positive Inotropy)                 Marked Vasodilation:
Preserves Diastolic Relaxation (Neutral Lusitropy)          Coronary, Systemic, and Pulmonary Beds
Avoids Arrhythmias & Minimizes MVO2                         Reduces Preload and Afterload

Mechanism of Action

1. Troponin C Sensitization: Levosimendan binds selectively to the calcium-saturated regulatory domain of cardiac troponin C (cTnC) during systole, stabilizing the conformational shift that permits actin-myosin interaction. Because it detaches from troponin C as intracellular calcium levels fall during diastole, it does not impede diastolic relaxation (preventing impaired lusitropy).
2. ATP-Sensitive Potassium ($K_{\text{ATP}}$) Channel Opening: In vascular smooth muscle and mitochondrial inner membranes, levosimendan activates $K_{\text{ATP}}$ channels. The resulting potassium efflux hyperpolarizes the sarcolemma, preventing voltage-gated calcium entry and triggering systemic, pulmonary, and coronary vasodilation.
3. Mitochondrial Protection: Opening of mitochondrial $K_{\text{ATP}}$ channels in cardiomyocytes confers preconditioning-like cardioprotection against ischemia-reperfusion injury.

Pharmacokinetics and Active Metabolites

• Parent Drug: Levosimendan has an elimination half-life of approximately 1 hour, metabolized primarily via conjugation with glutathione in the liver and intestinal microflora.
• Active Metabolite OR-1896: Approximately 5% of a dose is converted in the large intestine into the intermediate metabolite OR-1855, which is subsequently acetylated in the liver to the active metabolite OR-1896. OR-1896 possesses identical calcium-sensitizing and vasodilating properties as the parent drug but exhibits an extraordinary elimination half-life of 70 to 80 hours. Consequently, a single 24-hour continuous infusion ($0.05 - 0.2\text{ mcg/kg/min}$) produces sustained hemodynamic and inotropic benefits lasting 7 to 10 days.

---

5. Arginine Vasopressin (AVP)

Arginine vasopressin is an endogenous nonapeptide hormone synthesized by magnocellular neurosecretory cells in the supraoptic and paraventricular nuclei of the hypothalamus and stored in secretory granules of the posterior pituitary gland (neurohypophysis).

Receptor Classification and Second Messengers

Vasopressin in Acidotic and Refractory Shock

Under physiological conditions, vasopressin plays a minor role in baseline blood pressure regulation. However, during septic shock, cardiopulmonary bypass, and severe hemorrhagic shock, endogenous vasopressin stores are rapidly depleted within hours, leading to a state of relative vasopressin deficiency.

• Efficacy in Severe Acidemia: Catecholamines lose their vasopressor potency in severely acidemic environments (arterial $\text{pH} < 7.20$) because low extracellular pH uncouples $\beta$ and $\alpha_1$ adrenoceptors from their respective G-proteins and diminishes intracellular calcium sensitivity. In contrast, $V_1$ receptor signaling remains fully operational during severe acidosis, allowing vasopressin to restore vascular tone when massive doses of norepinephrine fail.
• Pulmonary Vascular Sparing: Vasopressin causes powerful systemic arterial constriction, but at clinical doses ($0.01 - 0.04\text{ units/min}$), it binds endothelial $V_1$ and oxytocin-like receptors within the pulmonary vascular bed, stimulating the release of endothelial nitric oxide (eNOS). As a result, vasopressin produces minimal pulmonary vasoconstriction and may even reduce the pulmonary-to-systemic vascular resistance ratio ($PVR/SVR$), making it exceptionally valuable in pulmonary hypertension and right ventricular failure.
• Clinical Dosing Rule: Vasopressin should be administered as a fixed-dose continuous infusion of $0.01 - 0.04\text{ units/min}$ (or $0.03\text{ units/min}$) without rapid upward titration; higher infusion rates ($>0.04 - 0.06\text{ units/min}$) provoke severe coronary, mesenteric, and cutaneous digital vasoconstriction.

---

6. Comprehensive Hemodynamic Comparison Table